Equities Analysts Offer Predictions for MIST FY2028 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities researchers at HC Wainwright decreased their FY2028 earnings per share (EPS) estimates for shares of Milestone Pharmaceuticals in a report released on Friday, March 20th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $0.45 for the year, down from their previous estimate of $0.53. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $0.92 EPS and FY2030 earnings at $1.70 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Friday, March 20th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The business had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $37.52 million.

A number of other research firms have also weighed in on MIST. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Wells Fargo & Company lifted their price target on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Zacks Research lowered Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Finally, TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Milestone Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $8.00.

Milestone Pharmaceuticals Stock Performance

Shares of MIST stock opened at $1.16 on Monday. The firm’s 50 day moving average is $1.77 and its 200 day moving average is $1.99. The stock has a market capitalization of $98.80 million, a P/E ratio of -1.47 and a beta of 0.48. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $3.06. The company has a current ratio of 8.01, a quick ratio of 8.24 and a debt-to-equity ratio of 1.37.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in MIST. Creative Planning boosted its stake in Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after buying an additional 10,000 shares during the period. Raymond James Financial Inc. increased its stake in Milestone Pharmaceuticals by 30.1% in the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after acquiring an additional 10,000 shares during the last quarter. Bay Rivers Group raised its holdings in shares of Milestone Pharmaceuticals by 72.9% in the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock valued at $58,000 after acquiring an additional 12,170 shares in the last quarter. Sapient Capital LLC bought a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter valued at about $25,000. Finally, Strategic Family Wealth Counselors L.L.C. bought a new stake in shares of Milestone Pharmaceuticals during the 4th quarter valued at about $25,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Insider Transactions at Milestone Pharmaceuticals

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 34,523 shares of the firm’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $1.93, for a total value of $66,629.39. Following the completion of the transaction, the chief executive officer directly owned 482,744 shares of the company’s stock, valued at $931,695.92. This trade represents a 6.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 113,693 shares of company stock valued at $233,347. Corporate insiders own 19.50% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.